Search

Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology

Media

Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncology.

https://www.gsk.com/en-gb/media/press-releases/results-from-phase-iii-patient-preference-study-of-gsk-s-votrient-pazopanib-vs-sutent-sunitinib-in-advanced-renal-cell-carcinoma-published-in-journal-of-clinical-oncology/

First published: 01 April 2014

Esmo Analyst Presentation 1 Oct 2012

Media

https://www.gsk.com/media/8251/esmo-analyst-presentation-1-oct-2012.pdf

First published: 06 June 2022

GSK announces positive vote from FDA panel for pazopanib in certain advanced soft tissue sarcomas

Media

GSK announced the ODAC voted 11:2 in support a favourable benefit; risk assessment for use of Votrient in patients with soft tissue sarcoma.

https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-vote-from-fda-panel-for-pazopanib-in-certain-advanced-soft-tissue-sarcomas/

First published: 20 March 2012

Merrill Lynch Conference Julian Heslp Cfo

Media

https://www.gsk.com/media/8324/merrill-lynch-conference-julian-heslp-cfo.pdf

First published: 07 June 2022

Investor Meetings 2010

Media

https://www.gsk.com/media/8325/investor-meetings-2010.pdf

First published: 07 June 2022

Investor Meetings 2010 (1)

Media

https://www.gsk.com/media/8333/investor-meetings-2010-1.pdf

First published: 07 June 2022

Regulatory Update - GSK announces EU submission seeking additional indication for Votrient® as maintenance therapy for advanced ovarian cancer

Media

GSK today announced submission to the European Medicines Agency of a variation to the Marketing Authorisation for Votrient® (pazopanib)

https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-eu-submission-seeking-additional-indication-for-votrient-as-maintenance-therapy-for-advanced-ovarian-cancer/

First published: 07 August 2013

Late Stage Pipeline Review

Media

https://www.gsk.com/media/8248/late-stage-pipeline-review.pdf

First published: 06 June 2022

GlaxoSmithKline receives unanimous FDA Panel approval recommendation for Votrient™

Media

the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC).

https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-unanimous-fda-panel-approval-recommendation-for-votrient/

First published: 05 October 2009

FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma

Media

GSK announced the U.S. FDA has approved Votrient for the treatment of soft tissue sarcoma who have received prior chemotherapy.

https://www.gsk.com/en-gb/media/press-releases/fda-approves-votrient-for-treatment-of-patients-with-certain-types-of-advanced-soft-tissue-sarcoma/

First published: 26 April 2012